Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

485 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients.
Zangari M, Aujay M, Zhan F, Hetherington KL, Berno T, Vij R, Jagannath S, Siegel D, Keith Stewart A, Wang L, Orlowski RZ, Belch A, Jakubowiak A, Somlo G, Trudel S, Bahlis N, Lonial S, Singhal S, Kukreti V, Tricot G. Zangari M, et al. Among authors: tricot g. Eur J Haematol. 2011 Jun;86(6):484-7. doi: 10.1111/j.1600-0609.2011.01602.x. Eur J Haematol. 2011. PMID: 21477075 Free article. Clinical Trial.
A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients.
Zangari M, Yaccoby S, Pappas L, Cavallo F, Kumar NS, Ranganathan S, Suva LJ, Gruenwald JM, Kern S, Zhan F, Esseltine D, Tricot G. Zangari M, et al. Among authors: tricot g. Haematologica. 2011 Feb;96(2):333-6. doi: 10.3324/haematol.2010.031302. Epub 2010 Oct 15. Haematologica. 2011. PMID: 20952514 Free PMC article.
Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens.
Zangari M, Fink L, Zhan F, Tricot G. Zangari M, et al. Among authors: tricot g. Clin Lymphoma Myeloma Leuk. 2011 Apr;11(2):228-36. doi: 10.1016/j.clml.2011.03.006. Epub 2011 Apr 8. Clin Lymphoma Myeloma Leuk. 2011. PMID: 21575928 Review.
Infection--an underappreciated cause of bone pain in multiple myeloma.
Desikan R, Barlogie B, Sethi R, Toor A, Spoon D, Angtuaco E, Vanhemert R, VijayaGopal A, Singhal S, Mehta J, Jagannath S, Munshi N, Zangari M, Fassas A, Tricot G, Anaissie E. Desikan R, et al. Among authors: tricot g. Br J Haematol. 2003 Mar;120(6):1047-50. doi: 10.1046/j.1365-2141.2003.04178.x. Br J Haematol. 2003. PMID: 12648075 Free article.
Survival after relapse following tandem autotransplants in multiple myeloma patients: the University of Arkansas total therapy I experience.
Fassas AB, Barlogie B, Ward S, Jagannath S, Vesole D, Mattox S, Siegel D, Muwalla F, Zangari M, Anaissie E, Rhee FV, Thertulien R, Lee CK, Desikan R, Arzumanian V, McCoy J, Tricot G. Fassas AB, et al. Among authors: tricot g. Br J Haematol. 2003 Nov;123(3):484-9. doi: 10.1046/j.1365-2141.2003.04646.x. Br J Haematol. 2003. PMID: 14617011 Free article.
Immunomodulatory drugs in multiple myeloma.
Zangari M, Elice F, Tricot G. Zangari M, et al. Among authors: tricot g. Expert Opin Investig Drugs. 2005 Nov;14(11):1411-8. doi: 10.1517/13543784.14.11.1411. Expert Opin Investig Drugs. 2005. PMID: 16255679 Review.
485 results